Tara Frenkl, Head of Global Medical Strategy and Integrated Evidence Generation at Bayer, shared a post on LinkedIn:
“I’m passionate about precision oncology – and here’s why: because patients with HER2-mutant non-small cell lung cancer deserve better.
We’re committed to advancing understanding, championing comprehensive testing, and developing innovative solutions for these patients.
Grateful for the incredible collaboration across the health care sector and cross-functional teams making this possible!
Read more below.
Our commitment to advancing care in HER2-mutant non-small cell lung cancer
Reflecting back on lung cancer awareness month, here’s something that drives me every single day: lung cancer isn’t just one disease. It’s so much more complex than that- a collection of distinct molecular subtypes, each with its own unique biology and challenges. And among these, HER2-mutant non-small cell lung cancer (NSCLC) stands out as an area with a high unmet need, and therefore advancements in their treatment and outcomes are needed for patients.
What really strikes me about this patient population is who they are. We’re talking about younger individuals, predominantly women, and many who have never smoked. These are people who often don’t fit the typical lung cancer profile, which means diagnoses can come late, and treatment options remain limited.
Our commitment at Bayer to precision oncology goes beyond research pipelines and clinical development. It’s personal. It’s about those living with HER2-mutated NSCLC and their families who are hoping for better options, effective treatments, and overall improved quality of life. Precision oncology allows us to have a deeper understanding of the disease at a molecular level, enabling clinicians to tailor treatment plans and target those unmet needs.
And here’s one thing I know for sure: progress doesn’t happen in isolation. It takes partnerships with clinicians, researchers, regulatory experts and patient experiences all working toward the same goal.
We’re actively building these deep collaborations because we know that’s how meaningful change happens for patients. And we’re committed to bringing forward innovative, personalized solutions for those who need it the most
I’m incredibly proud of the teams across our organization who are dedicated to understanding the molecular complexities of HER2 mutations and developing targeted approaches that address the specific drivers of this disease. The collaboration I’ve witnessed – with academia, across R&D, Medical Affairs, our diagnostic partners, and the broader oncology community – has been nothing short of inspiring!.
This journey in precision oncology isn’t easy, but it’s absolutely worth it. Every patient with HER2-mutant NSCLC deserves hope, deserves options, and deserves our unwavering commitment. And I’m energized knowing that our teams are pushing boundaries every day to make that a reality.
Let’s keep moving forward together!.”
Read more posts featuring Tara Frenkl on OncoDaily.